NextEra Energy stock price: NEE set for earnings-week test after insider sale filing
25 January 2026
1 min read

NextEra Energy stock price: NEE set for earnings-week test after insider sale filing

New York, Jan 25, 2026, 16:11 EST — Market closed.

  • NextEra Energy shares ended Friday down 0.3%, closing at $84.81 after swinging between $84.21 and $85.39 during the session.
  • A Form 4 filing revealed EVP Ronald R. Reagan offloaded 10,826 shares at $85 each, executing under a 10b5-1 plan.
  • NextEra will release its fourth-quarter and full-year 2025 results ahead of the NYSE open on Jan. 27.

NextEra Energy Inc (NEE) shares ended Friday down 0.31%, closing at $84.81. Trading picks up again Monday ahead of the utility’s earnings report due Tuesday. During the session, the stock fluctuated between $84.21 and $85.39 on roughly 13.3 million shares changing hands.

All eyes turn to Tuesday, when NextEra is set to release its fourth-quarter and full-year 2025 earnings ahead of the New York Stock Exchange opening. CEO John Ketchum and CFO Mike Dunne will break down the results during a 9 a.m. ET webcast. 1

The timing is crucial since utilities often act as “bond proxies” — a term for dividend payers that tend to track interest rate expectations — and this sector has been twitchy about changes in borrowing-cost outlooks. NextEra straddles the line between regulated utility profits and major clean-energy projects, drawing in and pushing away distinct investor groups in rapid succession.

Another development emerged late last week: a Form 4 filing revealed Ronald R. Reagan, an executive vice president, sold 10,826 shares at $85 each on Jan. 22, operating under a Rule 10b5-1 plan. Following this sale, he reported holding 15,643 shares directly and an additional 19,589 shares indirectly via a retirement savings plan trust. 2

Form 4 is the SEC filing insiders submit to disclose their trades. A 10b5-1 plan, meanwhile, is an automated trading strategy executives and companies often cite to show trades aren’t based on new, nonpublic info.

NextEra’s shift on Friday seemed modest compared to some regulated-utility rivals. Dominion Energy dropped 0.55%, Southern Co nudged up 0.03%, the S&P 500 closed almost unchanged, and the Dow fell 0.58%. 3

The environment remains unsettled. Friday saw megacap tech stocks lift the S&P 500 and Nasdaq, yet Intel’s steep drop and ongoing geopolitical worries kept investors cautious. 4

NextEra, headquartered in Juno Beach, Florida, operates Florida Power & Light along with a renewables and storage division that develops and owns power projects throughout North America. When the company reports, investors usually focus on utility rate growth, project execution, and financing conditions.

Some traders are reading the tape as a technical setup ahead of earnings. Investor’s Business Daily noted the stock is forming a base, with $87.53 flagged as a critical level to watch. 5

But earnings-week setups can unravel quickly. A weaker outlook, rising costs on new builds, or another surge in long-term yields might undercut demand for utility stocks and leave rate-sensitive names vulnerable.

NextEra is set to report earnings and provide an outlook update on Tuesday, Jan. 27.

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Blackstone stock slides into a make-or-break week: what BX investors are watching
Previous Story

Blackstone stock slides into a make-or-break week: what BX investors are watching

Texas Instruments stock (TXN) heads into earnings week after Friday dip — what to watch next
Next Story

Texas Instruments stock (TXN) heads into earnings week after Friday dip — what to watch next

Go toTop